Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®

por Liapis, Vasilios, Tieu, William, Rudd, Stacey E., Donnelly, Paul S., Wittwer, Nicole L., Brown, Michael P., Staudacher, Alexander H.
Publicado 2020

Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models

por Liapis, Vasilios, Tieu, William, Wittwer, Nicole L., Gargett, Tessa, Evdokiou, Andreas, Takhar, Prab, Rudd, Stacey E., Donnelly, Paul S., Brown, Michael P., Staudacher, Alexander H.
Publicado 2021

Enzyme mediated incorporation of zirconium-89 or copper-64 into a fragment antibody for same day imaging of epidermal growth factor receptor

por Rudd, Stacey E., Van Zuylekom, Jessica K., Raicevic, Anna, Pearce, Lesley A., Cullinane, Carleen, Williams, Charlotte C., Adams, Timothy E., Hicks, Rodney J., Donnelly, Paul S.
Publicado 2021

In Vitro and In Vivo Evaluation of (89)Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy

por Burvenich, Ingrid J.G., Lee, Fook-Thean, Guo, Nancy, Gan, Hui K., Rigopoulos, Angela, Parslow, Adam C., O'Keefe, Graeme J., Gong, Sylvia J., Tochon-Danguy, Henri, Rudd, Stacey E., Donnelly, Paul S., Kotsuma, Masakatsu, Ohtsuka, Toshiaki, Senaldi, Giorgio, Scott, Andrew M.
Publicado 2016

ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with (89)Zr-durvalumab (MEDI4736) PET/CT in stage III N...

por Hegi-Johnson, Fiona, Rudd, Stacey E, Wichmann, Christian, Akhurst, Tim, Roselt, Peter, Trinh, Jenny, John, Thomas, Devereux, Lisa, Donnelly, Paul S, Hicks, Rod, Scott, Andrew M, Steinfort, Daniel, Fox, Stephen, Blyth, Benjamin, Parakh, Sagun, Hanna, Gerard G, Callahan, Jason, Burbury, Kate, MacManus, Michael
Publicado 2022